190 related articles for article (PubMed ID: 33423780)
21. Immunity and squamous cell carcinoma of the anus: epidemiological, clinical and therapeutic aspects.
Pernot S; Terme M; Zaanan A; Tartour E; Weiss L; Taieb J
Clin Res Hepatol Gastroenterol; 2014 Feb; 38(1):18-23. PubMed ID: 23932704
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of human papillomavirus in anal squamous cell carcinoma.
Ravenda PS; Magni E; Botteri E; Manzotti M; Barberis M; Vacirca D; Trovato CM; Dell'Acqua V; Leonardi MC; Sideri M; Fazio N; Zampino MG
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1033-8. PubMed ID: 25209946
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy in Anal Cancer.
Phuong L; Rajdev L
Curr Oncol Rep; 2020 Jul; 22(9):94. PubMed ID: 32651760
[TBL] [Abstract][Full Text] [Related]
24. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Khawandanah M; Baxley A; Pant S
J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
[TBL] [Abstract][Full Text] [Related]
25. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal.
Eng C; Jácome AA; Das P; Chang GJ; Rodriguez-Bigas M; Skibber JM; Wolff RA; Qiao W; Xing Y; Sethi S; Ohinata A; Crane CH
Clin Colorectal Cancer; 2019 Dec; 18(4):301-306. PubMed ID: 31350201
[TBL] [Abstract][Full Text] [Related]
26. New approaches in palliative systemic therapy of anal squamous cell carcinoma.
Lohynská R; Pechačová Z
Klin Onkol; 2022; 35(3):190-194. PubMed ID: 35760571
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in advanced anal cancer: Is the beginning of a new era?
Ciardiello D; Guerrera LP; Maiorano BA; Parente P; Latiano TP; Di Maio M; Ciardiello F; Troiani T; Martinelli E; Maiello E
Cancer Treat Rev; 2022 Apr; 105():102373. PubMed ID: 35279535
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy.
Rödel F; Wieland U; Fraunholz I; Kitz J; Rave-Fränk M; Wolff HA; Weiss C; Wirtz R; Balermpas P; Fokas E; Rödel C
Int J Cancer; 2015 Jan; 136(2):278-88. PubMed ID: 24839133
[TBL] [Abstract][Full Text] [Related]
29. Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.
Kim S; Boustani J; Vernerey D; Vendrely V; Evesque L; Francois E; Quero L; Ghiringhelli F; de la Fouchardière C; Dahan L; Bouché O; Chibaudel B; Hajbi FE; Vernet C; Rebucci-Peixoto M; Feuersinger A; Maritaz C; Borg C
Front Oncol; 2022; 12():918499. PubMed ID: 36119522
[TBL] [Abstract][Full Text] [Related]
30. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH
Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775
[TBL] [Abstract][Full Text] [Related]
31. Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal.
Morris VK; Eng C
J Natl Compr Canc Netw; 2018 Jul; 16(7):903-908. PubMed ID: 30006430
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
33. Metastatic Anal Cancer and Novel Agents.
Morris V; Eng C
Surg Oncol Clin N Am; 2017 Jan; 26(1):133-142. PubMed ID: 27889032
[TBL] [Abstract][Full Text] [Related]
34. Progress in the treatment of anal cancer: an overview of the latest investigational drugs.
Yu J; Kim RD
Expert Opin Investig Drugs; 2024 Feb; 33(2):145-157. PubMed ID: 38275174
[TBL] [Abstract][Full Text] [Related]
35. HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma.
Soares PC; Abdelhay ES; Thuler LCS; Soares BM; Demachki S; Ferro GVR; Assumpção PP; Lamarão LM; Ribeiro Pinto LF; Burbano RMR
BMC Gastroenterol; 2018 Feb; 18(1):30. PubMed ID: 29466950
[TBL] [Abstract][Full Text] [Related]
36. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
[TBL] [Abstract][Full Text] [Related]
37. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor inhibition in metastatic anal cancer.
Rogers JE; Ohinata A; Silva NN; Mehdizadeh A; Eng C
Anticancer Drugs; 2016 Sep; 27(8):804-8. PubMed ID: 27272412
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in Anal Cancer.
Dhawan N; Afzal MZ; Amin M
Curr Oncol; 2023 Apr; 30(5):4538-4550. PubMed ID: 37232801
[TBL] [Abstract][Full Text] [Related]
40. Optimal management of squamous cell carcinoma of the anal canal: where are we now?
Eng C; Ahmed S
Expert Rev Anticancer Ther; 2014 Aug; 14(8):877-86. PubMed ID: 24981728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
